Ziprasidone

doi:10.2165/00023210-200620120-00006

Paper

Ziprasidone

Published 2006 · T. S. Harrison, L. Scott

CNS Drugs

Q1 SJR score

40

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Ziprasidone (Geodon, Zeldox) is an atypical antipsychotic agent with a unique neurotransmitter receptor-binding profile. The oral formulation is indicated for the treatment of adult patients with schizophrenia and the intramuscular formulation for the control of acute agitation in these patients. In adult patients with schizophrenia or schizoaffective disorder, oral ziprasidone was effective at a dosage of 40-80 mg twice daily in patients experiencing a phase of acute illness, and at a dosage of 20-80 mg twice daily in those with chronic schizophrenia or schizoaffective disorder, including those who were symptomatically stable. Ziprasidone offers the advantage over most other atypical antipsychotic agents of being available in a fast-acting intramuscular formulation for control of acute agitation, thus providing clinicians with the option to safely and effectively transition to longer-term treatment with the oral formulation. Although careful consideration should be given to the propensity for ziprasidone to cause corrected QT (QTc) interval prolongation, albeit at a relatively low incidence, the drug generally has a favourable tolerability profile of low extrapyramidal syndrome (EPS) liability, neutral bodyweight gain, and potentially low propensity for metabolic complications. Thus, ziprasidone is an effective option for the management of patients with schizophrenia or schizoaffective disorder, with the intramuscular formulation providing a useful option for the treatment of acute agitation in these patients.

Study Snapshot

Ziprasidone is an effective atypical antipsychotic for treating adult patients with schizophrenia or schizoaffective disorder, with an intramuscular formulation for treating acute agitation.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Ziprasidone

Sign up to use Study Snapshot

References

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study

Ziprasidone and amisulpride are both effective in treating negative symptoms and overall psychopathology in patients with predominantly negative-symptom schizophrenia.

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

Clozapine is more effective than other newer atypical antipsychotics for patients with schizophrenia who failed to improve with prior treatment, but safety monitoring is necessary due to serious side effects.

A 24-Week Randomized Study of Olanzapine Versus Ziprasidone in the Treatment of Schizophrenia or Schizoaffective Disorder in Patients with Prominent Depressive Symptoms

Olanzapine shows greater improvements in depressive symptoms and global assessment of functioning for 24 weeks compared to ziprasidone, with greater sustained participation in treatment.

Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic

Olanzapine, quetiapine, risperidone, and ziprasidone show similar effectiveness in treating chronic schizophrenia after discontinuing a previous atypical antipsychotic.

Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia

Ziprasidone is more effective and tolerable than chlorpromazine in treating treatment-resistant schizophrenia, with greater improvements in efficacy at weeks 3 and 6.

Citations

Drugs and Their Mode of Action: A Review on Sulfur-Containing Heterocyclic Compounds

Sulfur-containing heterocyclic compounds show diverse pharmacological activities and unique modes of action, with ring size influencing medicinal potency and their potential as drug candidates for treating various diseases.

Exploration of the potential neuroprotective compounds targeting GluN1-GluN2B NMDA receptors

Talniflumate shows potential as a safe and efficient neuroprotective compound targeting GluN1-GluN2B NMDA receptors through virtual screening.

Comparative study of performances of UHPLC-MS/MS and HPLC/UV methods for analysis of ziprasidone and its main impurities

The UHPLC-MS/MS method is more selective and sensitive than HPLC-UV methods for analyzing ziprasidone and its main impurities, making it a greener and faster method for routine control.

Case Report: Ziprasidone induced neuroleptic malignant syndrome

Ziprasidone use at therapeutic dose can cause neuroleptic malignant syndrome, potentially fatal and causing significant morbidity and complications.

Algorithm‐based pharmacotherapy for first‐episode schizophrenia involuntarily hospitalized: A retrospective analysis of real‐world practice

Algorithm-based pharmacotherapy (ABP) is feasible and effective in treating first-episode schizophrenia involuntarily hospitalized patients, with improved clinical outcomes.

A Combined Utilization of Plasdone-S630 and HPMCAS-HF in Ziprasidone Hydrochloride Solid Dispersion by Hot-Melt Extrusion to Enhance the Oral Bioavailability and No Food Effect

The combination of Plasdone-S630 and HPMCAS-HF in hot-melt extrusion of ziprasidone hydrochloride solid dispersion enhances oral bioavailability and eliminates food effect, making it a promising drug for fasted treatment.

Ultra-performance liquid chromatography tandem mass spectrometry for the rapid, simultaneous analysis of ziprasidone and its impurities.

The developed UHPLC-MS/MS method effectively separates and identifies ziprasidone and its main impurities, enabling genotoxic potential assessment.

Use of Solid Dispersions and Inclusion Complexation for Enhancing Oral Bioavailability of Ziprasidone in Treating Schizophrenia

Solid dispersion and inclusion complexation techniques can enhance the oral bioavailability of Ziprasidone for treating schizophrenia, with Soluplus-solid dispersion being the most suitable for enhancing absorption and decreasing dose.